Elicera Therapeutics (Q2 review): Progress in CARMA-study - Redeye

Redeye returns with an update following Elicera's Q2 report and recent events in the company, including a new CEO and data from the CARMA-study with ELC-301. Elicera Screens "attractively priced" in our new market edge system.

Länk till analysen i sin helhet: https://www.redeye.se/research/1183866/elicera-therapeutics-q2-review-progress-in-carma-study?utm_source=finwire&utm_medium=RSS